A groundbreaking discovery in molecular biology could revolutionize the management of coeliac disease, offering a potential solution to a long-standing challenge in healthcare. The research, conducted by a collaborative team from the Institute for Research in Nutrition and Food Safety (INSA), the University of Barcelona's Faculty of Pharmacy and Food Sciences, and the Molecular Biology Institute of Barcelona (IBMB) of the CSIC, has led to the development of a novel gluten-degrading molecule named celiacase.
Coeliac disease, an autoimmune condition triggered by gluten and other prolamins in cereals, currently lacks effective treatment options beyond a strict gluten-free diet. This diet is often difficult to maintain in Western cultures, where wheat products are prevalent. The new molecule, celiacase, offers a promising alternative by effectively neutralizing gluten at very low concentrations and in the acidic environment of the stomach (pH 2), a feat previously unachieved by existing molecules.
The key to celiacase's success lies in its design. Based on a molecule called nephrosin, found in the digestive juices of carnivorous plants, it can degrade gluten's toxic fragments, known as gluten immunogenic peptides (GIPs), before they reach the small intestine. Among these GIPs, the '33-mer' is particularly immunogenic, triggering an autoimmune response in coeliac patients. By targeting and breaking down these harmful peptides, celiacase has the potential to prevent the onset of symptoms.
In a mouse model developed by the University of Chicago, celiacase demonstrated remarkable efficacy. Even at high gluten intake levels, it mitigated symptoms such as intestinal atrophy, inflammation, and dysbiosis, while restoring normal levels of immunoregulatory markers and microbial metabolic pathways. This suggests that celiacase could be a valuable adjunct to gluten-free diets, offering a more comprehensive approach to managing coeliac disease.
Furthermore, celiacase's design ensures that it is no longer active once it reaches the duodenum, the part of the small intestine where digestion continues. This prevents interference with other proteins in the body, making it a more targeted and safe therapeutic option. The molecule has been patented, and the team is exploring the establishment of a spin-off company to advance its development.
This breakthrough in molecular biology not only offers hope for coeliac patients but also highlights the potential of innovative approaches in healthcare. As the team continues to refine and develop celiacase, the future of coeliac disease management may be transformed, providing a more sustainable and effective solution for those affected by this challenging condition.
